67.3 Primary Care During Cancer Treatment & Survivorship
Key Takeaways
- Febrile neutropenia is a single oral temperature of at least 38.3 C, or at least 38.0 C sustained an hour, with an ANC below 500/uL or expected to fall below 500 within 48 hours, and it requires empiric antipseudomonal antibiotics within 1 hour.
- New diarrhea, hepatitis, pneumonitis, thyroiditis, or hypophysitis in a patient on a checkpoint inhibitor is an immune-related adverse event; grade 2 or higher events require holding the drug and starting corticosteroids.
- New back pain in a patient with known malignancy warrants immediate dexamethasone and urgent MRI of the entire spine before neurologic deficits develop.
- Anthracycline cardiotoxicity is dose-dependent and largely irreversible near a cumulative doxorubicin dose of 450 to 550 mg/m2, while trastuzumab cardiotoxicity is not dose-dependent and is often reversible with interruption.
- Live vaccines are contraindicated during active chemotherapy, but inactivated and recombinant vaccines including recombinant zoster vaccine are indicated, and resuming routine screening for other cancers is the most commonly missed element of survivorship care.
The Family Physician's Two Oncology Roles
The blueprint activity "disease management related to cancer treatment" sits in Chronic Care Management, and it captures two distinct jobs that family physicians perform far more often than they perform cancer diagnosis:
- Caring for the patient who is currently on treatment — recognizing the handful of true oncologic emergencies, managing common toxicities, and knowing what must be escalated the same day.
- Caring for the survivor — surveillance for recurrence and second primaries, management of long-term and late effects, and reintegration of routine preventive care that was suspended during treatment.
Neither job requires prescribing chemotherapy. Both require knowing exactly where the primary care threshold for urgency sits.
Emergencies in the Patient on Active Treatment
Febrile neutropenia — the highest-stakes recognition on the blueprint
Definition: a single oral temperature ≥ 38.3 °C (101 °F), or a temperature ≥ 38.0 °C (100.4 °F) sustained for at least 1 hour, in a patient with an absolute neutrophil count (ANC) below 500 cells/µL, or an ANC expected to fall below 500 within the next 48 hours.
- The nadir typically occurs 7 to 14 days after a cytotoxic cycle.
- Fever may be the only sign. Neutropenic patients cannot mount the erythema, fluctuance, or infiltrate that normally localize infection, so a normal chest radiograph and a benign examination do not reassure.
- Empiric broad-spectrum antibiotics with antipseudomonal coverage must be given within 1 hour of presentation — cefepime, piperacillin-tazobactam, or a carbapenem. Cultures should be drawn but must not delay the first dose.
- Add vancomycin for hemodynamic instability, suspected catheter-related infection, skin or soft-tissue infection, pneumonia, or known MRSA colonization — it is not part of routine initial coverage.
- The MASCC risk index identifies low-risk patients (score ≥ 21) who may be candidates for oral therapy (ciprofloxacin plus amoxicillin-clavulanate) and outpatient management, but this decision belongs with oncology, not with an unsupported office triage.
- Do not administer antipyretics and observe, and do not defer antibiotics pending culture results or an oncology callback. Sending a febrile neutropenic patient home from clinic is a recurring wrong answer.
Other must-not-miss presentations
| Emergency | Classic presentation | Immediate action |
|---|---|---|
| Malignant spinal cord compression | New or worsening back pain, worse when supine or with Valsalva; later leg weakness, sensory level, bowel/bladder dysfunction | Dexamethasone immediately plus urgent MRI of the entire spine; do not wait for neurologic deficit to image |
| Hypercalcemia of malignancy | Confusion, constipation, polyuria, dehydration, shortened QT | Isotonic saline volume repletion plus IV bisphosphonate (zoledronic acid); calcitonin for rapid short-term lowering; avoid loop diuretics as a primary strategy |
| Tumor lysis syndrome | Within days of treating a bulky or highly proliferative tumor: hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, acute kidney injury | Aggressive IV fluids, allopurinol for prophylaxis or rasburicase for established/high-risk disease, urgent electrolyte management |
| Superior vena cava syndrome | Facial and upper-extremity swelling, distended neck veins, dyspnea worse when supine | Urgent imaging and oncology referral; airway compromise or cerebral edema makes it emergent |
| Immune-related adverse events (irAEs) | Any new colitis, hepatitis, pneumonitis, thyroiditis, hypophysitis, nephritis, or rash in a patient on a checkpoint inhibitor | Grade ≥ 2: hold the drug and start corticosteroids after urgent discussion with oncology |
[!IMPORTANT] Checkpoint inhibitor diarrhea is not gastroenteritis. New diarrhea in a patient on pembrolizumab, nivolumab, or ipilimumab is immune-mediated colitis until proved otherwise. Treating it with loperamide alone and waiting delays corticosteroids and risks perforation. Similarly, fatigue plus hyponatremia in a checkpoint-inhibitor patient should raise hypophysitis (most classically with ipilimumab) and prompt evaluation of the pituitary–adrenal axis.
Common Toxicities Managed in Primary Care
| Toxicity | Typical agents | Practical management |
|---|---|---|
| Chemotherapy-induced nausea and vomiting | Cisplatin, anthracycline–cyclophosphamide | Prophylaxis, not rescue: 5-HT3 antagonist + dexamethasone + NK1 antagonist ± olanzapine for highly emetogenic regimens |
| Chemotherapy-induced peripheral neuropathy | Platinums, taxanes, vinca alkaloids, bortezomib | Duloxetine is the only agent with meaningful supporting evidence; there is no effective preventive agent |
| Mucositis | 5-fluorouracil, methotrexate, radiation | Bland oral rinses, analgesia, nutrition support; assess for candidiasis and HSV |
| Anthracycline cardiotoxicity | Doxorubicin (cumulative dose limit approximately 450–550 mg/m²) | Dose-dependent and largely irreversible; serial LVEF assessment |
| Trastuzumab cardiotoxicity | HER2-directed therapy | Not dose-dependent and often reversible with interruption; LVEF monitoring roughly every 3 months |
| Cancer-related fatigue | Nearly all modalities | The most prevalent symptom of treatment; exercise has the strongest evidence, ahead of any pharmacologic option |
Vaccination during treatment
Live vaccines are contraindicated during active chemotherapy and other significant immunosuppression (MMR, varicella, live attenuated influenza, and the older live zoster vaccine). Inactivated and recombinant vaccines are indicated and encouraged, including inactivated influenza, COVID-19, and recombinant zoster vaccine. Timing is best coordinated with the treatment cycle so that vaccination does not fall at the neutrophil nadir. Household contacts should be fully vaccinated.
Survivorship Care
More than 18 million cancer survivors live in the United States, and most of their long-term care is delivered in primary care. A survivorship care plan should be obtained or reconstructed at the first post-treatment visit and contains two parts: a treatment summary (diagnosis, stage, surgery, cumulative chemotherapy doses, radiation fields and dose, and biologic agents) and a follow-up plan (surveillance schedule, expected late effects, and division of responsibility between oncology and primary care).
Long-term and late effects worth memorizing
| Exposure | Late effect to anticipate |
|---|---|
| Anthracyclines | Cardiomyopathy and heart failure, often years later |
| Chest radiation | Premature coronary disease, valvular disease, hypothyroidism, second primary breast cancer — breast MRI surveillance is added for chest irradiation received between roughly ages 10 and 30 |
| Neck radiation | Hypothyroidism (check TSH periodically), carotid disease |
| Aromatase inhibitors | Arthralgia and accelerated bone loss — bone density monitoring and calcium/vitamin D |
| Tamoxifen | Endometrial carcinoma and venous thromboembolism risk; abnormal uterine bleeding requires prompt evaluation, but routine endometrial surveillance of asymptomatic users is not recommended |
| Androgen deprivation therapy | Osteoporosis, metabolic syndrome, hot flashes, sexual dysfunction |
| Platinum agents | Persistent peripheral neuropathy, ototoxicity, nephrotoxicity |
| Alkylating agents | Premature ovarian insufficiency, infertility, secondary hematologic malignancy |
| Axillary or inguinal node dissection | Lymphedema — early referral to lymphedema therapy improves outcomes |
| Any curative treatment | Cognitive changes, fatigue, sexual dysfunction, fear of recurrence, financial toxicity |
The primary care survivorship checklist
- Resume and complete routine preventive care. Screening for cancers other than the treated one, immunizations, blood pressure, lipids, and diabetes screening are frequently abandoned during treatment years and are the most common survivorship care gap.
- Surveillance per the plan, not by symptom-driven scanning. For most solid tumors, intensive imaging surveillance of asymptomatic survivors does not improve survival, and tumor-marker testing outside guideline indications generates anxiety and false alarms.
- Manage cardiovascular risk aggressively — cardiovascular disease, not recurrence, is a leading cause of death in long-term survivors of several common cancers.
- Address psychosocial and sexual health explicitly; both are under-asked and highly prevalent.
- Discuss family risk. A survivor with early-onset disease or a suggestive family history warrants genetic counseling referral, which also affects relatives.
Board Exam Traps
- Fever 10 days after chemotherapy, benign examination, normal chest film → this is febrile neutropenia until the ANC proves otherwise; give antipseudomonal antibiotics within an hour and admit, rather than reassuring and rechecking.
- Diarrhea on a checkpoint inhibitor → immune-mediated colitis; hold the drug and start corticosteroids for grade 2 or higher, not loperamide alone.
- New back pain in a patient with metastatic prostate or breast cancer → dexamethasone and urgent whole-spine MRI before deficits appear.
- Zoster vaccination request during active chemotherapy → recombinant zoster vaccine is not live and is appropriate; the live attenuated products are contraindicated.
- A breast cancer survivor 4 years out asking about "the scan that catches recurrence" → guideline-concordant surveillance is history, examination, and mammography; routine PET or tumor markers in asymptomatic survivors are not recommended.
- A 5-year survivor overdue for colorectal and cervical screening → resuming standard preventive care is the intervention with the clearest survival benefit at this visit.
A 61-year-old woman receiving adjuvant chemotherapy for breast cancer calls the office on day 11 of her cycle reporting an oral temperature of 38.6 C (101.5 F). She feels tired but has no cough, dysuria, or localizing symptoms. In the office she is well appearing, blood pressure is 118/72 mm Hg, and lung fields are clear. Which is the most appropriate management?
A 68-year-old man with metastatic melanoma began pembrolizumab 6 weeks ago. He reports 5 days of watery diarrhea, now 7 stools daily, with mild abdominal cramping and no fever or blood. Stool studies including Clostridioides difficile testing are negative. What is the most appropriate management?
A 54-year-old woman completed treatment for stage II breast cancer 3 years ago, including doxorubicin-based chemotherapy and 5 years of planned anastrozole. She has no symptoms. Which of the following is the most appropriate element of her survivorship care at this visit?